Shots:
- Medgene has entered into an agreement with Elanco to commercialize Medgene’s highly pathogenic avian influenza (HPAI/H5N1) vaccine in the US for dairy cattle
- Medgene’s vaccine has met all USDA platform tech guidelines & is in final review for conditional approval, with manufacturing supply ready for deployment upon approval
- HPAI vaccine is developed using Medgene’s bioinformatics software
Ref: Elanco | Image: Elanco
Related News:- Elanco Animal Health Reports the US FDA’s Approval of Credelio Quattro for Protection Against Parasites in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.co
